Furthermore, the KRAS protein and DNA vaccines have emerged as a novel immunotherapeutic strategy to tackle oncogenic KRAS-addicted cancers in preclinical models or as adjuvant treatment options in clinical settings. Here, KRAS is linked to cancer.